市場調査レポート

商品コード

1178050

抗凝固剤の世界市場：薬剤クラス（第XA因子阻害剤（NOAC/DOAC）、ヘパリン、直接トロンビン阻害剤、ビタミンK拮抗剤）－業界分析、市場規模、シェア、成長、動向、予測（2022年～2031年）

Anticoagulants Market (Drug Class: Factor XA Inhibitors [NOAC/DOAC], Heparins, and Direct Thrombin inhibitors, and Vitamin K Antagonists) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

出版日: 2022年11月04日 | 発行: Transparency Market Research

| ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 5,795 907,381円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Multi-user License)

USD 8,795 1,377,121円

レポートPDFを同一の部署内・課内の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Corporate License)

USD 11,795 1,846,861円

レポートPDFを企業内すべての方に使用頂けるライセンスです。ご利用人数の制限はありません。 PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.58円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

当レポートでは、世界の抗凝固剤市場について調査分析し、市場概要、市場分析、競合情勢など、体系的な情報を提供しています。

市場参入企業：競合マトリックス（層および企業規模別）
市場シェア/ランキング分析（2021年）：企業別
企業プロファイル
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb
- Daiichi Sankyo Company
- Sanofi
- Johnson &Johnson
- Pfizer, Inc.

図表

List of Tables

Table 01: Global Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031
Table 02: Global Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031
Table 03: Global Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031
Table 04: Global Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031
Table 05: Global Anticoagulants Market Size (US$ Bn) and Volume (Units) Forecast, by Region, 2017-2031
Table 06: North America Anticoagulants Market Value (US$ Bn) Forecast, by Country, 2017-2031
Table 07: North America Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031
Table 08: North America Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031
Table 09: North America Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031
Table 10: North America Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031
Table 11: Europe Anticoagulants Size Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 12: Europe Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031
Table 13: Europe Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031
Table 14: Europe Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031
Table 15: Europe Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031
Table 16: Asia Pacific Anticoagulants Size Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031
Table 18: Asia Pacific Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031
Table 19: Asia Pacific Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031
Table 20: Asia Pacific Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031
Table 21: Latin America Anticoagulants Size Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031
Table 23: Latin America Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031
Table 24: Latin America Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031
Table 25: Latin America Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031
Table 26: Middle East & Africa Anticoagulants Size Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Anticoagulants Market Value (US$ Bn) Forecast, by Route of Administration, 2017-2031
Table 28: Middle East & Africa Anticoagulants Market Value (US$ Bn) Forecast, by Drug Class, 2017-2031
Table 29: Middle East & Africa Anticoagulants Market Value (US$ Bn) Forecast, by Indication, 2017-2031
Table 30: Middle East & Africa Anticoagulants Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031

List of Figures

Figure 01: Global Anticoagulants Market Snapshot
Figure 02: Global Anticoagulants Market Segments With Leading Market Share (%), 2021
Figure 03: Key Industry Developments (Anticoagulants Market)
Figure 04: Global Anticoagulants Market Value (US$ Bn) Forecast, 2017-2027
Figure 05: Global Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021
Figure 06: Global Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021
Figure 07: Global Anticoagulants Market Value Share Analysis (%), by Indication, 2021
Figure 08: Global Anticoagulants Market Value Share Analysis (%), by Distribution Channel, 2021
Figure 09: Global Anticoagulants Market Value Share Analysis (%), by Region, 2021
Figure 10: Global Anticoagulants Market Value Share Analysis, by Drug Class, 2021 and 2031
Figure 11: Global Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022-2031
Figure 12: Global Anticoagulants Market Value Share Analysis, by Route of Administration, 2021 and 2031
Figure 13: Global Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 14: Global Anticoagulants Market Value Share Analysis, by Indication, 2021 and 2031
Figure 15: Global Anticoagulants Market Attractiveness Analysis, by Indication, 2022-2031
Figure 16: Global Anticoagulants Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 17: Global Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 18: Global Anticoagulants Market Value Share Analysis, by Region, 2021 and 2031
Figure 19: Global Anticoagulants Market Attractiveness Analysis, by Region, 2017-2031
Figure 20: North America Anticoagulants Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 21: North America Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021 and 2031
Figure 22: North America Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022-2031
Figure 23: North America Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021 and 2031
Figure 24: North America Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 25: North America Anticoagulants Market Value Share Analysis (%), by Indication, 2021 and 2031
Figure 26: North America Anticoagulants Market Attractiveness Analysis, by Indication, 2022-2031
Figure 27: North America Anticoagulants Market Value Share Analysis (%), by Distribution Channel, 2021 and 2031
Figure 28: North America Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 29: North America Anticoagulants Market Value Share Analysis (%), by Country, 2021 and 2031
Figure 30: North America Anticoagulants Market Attractiveness Analysis, by Country, 2021 and 2031
Figure 31: Europe Anticoagulants Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 32: Europe Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021 and 2031
Figure 33: Europe Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022-2031
Figure 34: Europe Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021 and 2031
Figure 35: Europe Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 36: Europe Anticoagulants Market Value Share Analysis (%), by Indication, 2021 and 2031
Figure 37: Europe Anticoagulants Market Attractiveness Analysis, by Indication, 2022-2031
Figure 38: Europe Anticoagulants Market Value Share Analysis (%), by Distribution Channel, 2021 and 2031
Figure 39: Europe Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 40: Europe Anticoagulants Market Value Share Analysis (%), by Country/Sub-region, 2021 and 2031
Figure 41: Europe Anticoagulants Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 42: Asia Pacific Anticoagulants Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 43: Asia Pacific Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021 and 2031
Figure 44: Asia Pacific Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022-2031
Figure 45: Asia Pacific Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021 and 2031
Figure 46: Asia Pacific Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 47: Asia Pacific Anticoagulants Market Value Share Analysis (%), by Indication, 2021 and 2031
Figure 48: Asia Pacific Anticoagulants Market Attractiveness Analysis, by Indication, 2022-2031
Figure 49: Asia Pacific Anticoagulants Value Share Analysis (%), by Distribution Channel, 2021 and 2031
Figure 50: Asia Pacific Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 51: Asia Pacific Anticoagulants Market Value Share Analysis (%), by Country/Sub-region, 2021 and 2031
Figure 52: Asia Pacific Anticoagulants Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 53: Latin America Anticoagulants Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 54: Latin America Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021 and 2031
Figure 55: Latin America Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022-2031
Figure 56: Latin America Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021 and 2031
Figure 57: Latin America Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 58: Latin America Anticoagulants Market Value Share Analysis (%), by Indication, 2021 and 2031
Figure 59: Latin America Anticoagulants Market Attractiveness Analysis, by Indication, 2022-2031
Figure 60: Latin America Anticoagulants Value Share Analysis (%), by Distribution Channel, 2021 and 2031
Figure 61: Latin America Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 62: Latin America Anticoagulants Market Value Share Analysis (%), by Country/Sub-region, 2021 and 2031
Figure 63: Latin America Anticoagulants Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Figure 64: Middle East & Africa Anticoagulants Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031
Figure 65: Middle East & Africa Anticoagulants Market Value Share Analysis (%), by Drug Class, 2021 and 2031
Figure 66: Middle East & Africa Anticoagulants Market Attractiveness Analysis, by Drug Class, 2022-2031
Figure 67: Middle East & Africa Anticoagulants Market Value Share Analysis (%), by Route of Administration, 2021 and 2031
Figure 68: Middle East & Africa Anticoagulants Market Attractiveness Analysis, by Route of Administration, 2022-2031
Figure 69: Middle East & Africa Anticoagulants Market Value Share Analysis (%), by Indication, 2021 and 2031
Figure 70: Middle East & Africa Anticoagulants Value Share Analysis (%), by Distribution Channel, 2021 and 2031
Figure 71: Middle East & Africa Anticoagulants Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 72: Middle East & Africa Anticoagulants Market Value Share Analysis (%), by Country/Sub-region, 2021 and 2031
Figure 73: Middle East & Africa Anticoagulants Market Attractiveness Analysis, by Country/Sub-region, 2022-2031

Product Code: TMRGL60924

TMR's report on the global anticoagulants market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global anticoagulants market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anticoagulants market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the anticoagulants market.

The report delves into the competitive landscape of the global anticoagulants market. Key players operating in the global anticoagulants market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global anticoagulants market profiled in this report.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Anticoagulants Market

4. Market Overview

4.1. Introduction
- 4.1.1. Segment Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Anticoagulants Market Analysis and Forecast, 2017-2031
- 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

5.1. Key industry events (mergers & acquisitions, product launches, partnerships, etc.)
5.2. Overview on the Novel Oral Anticoagulants (NOACs)
5.3. Epidemiology of the Key Diseases
5.4. Covid-19 Pandemic Impact on the Industry

6. Global Anticoagulants Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017-2031
- 6.3.1. Factor XA Inhibitors (NOAC/DOAC)
- 6.3.2. Heparins
- 6.3.3. Direct Thrombin Inhibitors
- 6.3.4. Vitamin K Antagonists
6.4. Market Attractiveness Analysis, by Drug Class

7. Global Anticoagulants Market Analysis and Forecast, by Route of Administration

7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017-2031
- 7.3.1. Oral
- 7.3.2. Injectable
7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Anticoagulants Market Analysis and Forecast, by Indication

8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Indication, 2017-2031
- 8.3.1. Deep Vein Thrombosis
- 8.3.2. Pulmonary Embolism
- 8.3.3. Atrial Fibrillation & Heart Attack
- 8.3.4. Ischemic Stroke
- 8.3.5. Others
8.4. Market Attractiveness Analysis, by Indication

9. Global Anticoagulants Market Analysis and Forecast, by Distribution Channel

9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 9.3.1. Hospital Pharmacies
- 9.3.2. Retail Pharmacies
- 9.3.3. Online Pharmacies
9.4. Market Attractiveness Analysis, by Distribution Channel

10. Global Anticoagulants Market Analysis and Forecast, by Region

10.1. Key Findings
10.2. Market Value Forecast, by Region
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region

11. North America Anticoagulants Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017-2031
- 11.2.1. Factor XA Inhibitors (NOAC/DOAC)
- 11.2.2. Heparins
- 11.2.3. Direct Thrombin Inhibitors
- 11.2.4. Vitamin K Antagonists
11.3. Market Value Forecast, by Route of Administration, 2017-2031
- 11.3.1. Oral
- 11.3.2. Injectable
11.4. Market Value Forecast, by Indication, 2017-2031
- 11.4.1. Deep Vein Thrombosis
- 11.4.2. Pulmonary Embolism
- 11.4.3. Atrial Fibrillation & Heart Attack
- 11.4.4. Ischemic Stroke
- 11.4.5. Others
11.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 11.5.1. Hospital Pharmacies
- 11.5.2. Retail Pharmacies
- 11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country, 2017-2031
- 11.6.1. U.S.
- 11.6.2. Canada
11.7. Market Attractiveness Analysis
- 11.7.1. By Drug Class
- 11.7.2. By Route of Administration
- 11.7.3. By Indication
- 11.7.4. By Distribution Channel
- 11.7.5. By Country

12. Europe Anticoagulants Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017-2031
- 12.2.1. Factor XA Inhibitors (NOAC/DOAC)
- 12.2.2. Heparins
- 12.2.3. Direct Thrombin Inhibitors
- 12.2.4. Vitamin K Antagonists
12.3. Market Value Forecast, by Route of Administration, 2017-2031
- 12.3.1. Oral
- 12.3.2. Injectable
12.4. Market Value Forecast, by Indication, 2017-2031
- 12.4.1. Deep Vein Thrombosis
- 12.4.2. Pulmonary Embolism
- 12.4.3. Atrial Fibrillation & Heart Attack
- 12.4.4. Ischemic Stroke
- 12.4.5. Others
12.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 12.5.1. Hospital Pharmacies
- 12.5.2. Retail Pharmacies
- 12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.6.1. Germany
- 12.6.2. U.K.
- 12.6.3. France
- 12.6.4. Italy
- 12.6.5. Spain
- 12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
- 12.7.1. By Drug Class
- 12.7.2. By Route of Administration
- 12.7.3. By Indication
- 12.7.4. By Distribution Channel
- 12.7.5. By Country/Sub-region

13. Asia Pacific Anticoagulants Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017-2031
- 13.2.1. Factor XA Inhibitors (NOAC/DOAC)
- 13.2.2. Heparins
- 13.2.3. Direct Thrombin Inhibitors
- 13.2.4. Vitamin K Antagonists
13.3. Market Value Forecast, by Route of Administration, 2017-2031
- 13.3.1. Oral
- 13.3.2. Injectable
13.4. Market Value Forecast, by Indication, 2017-2031
- 13.4.1. Deep Vein Thrombosis
- 13.4.2. Pulmonary Embolism
- 13.4.3. Atrial Fibrillation & Heart Attack
- 13.4.4. Ischemic Stroke
- 13.4.5. Others
13.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 13.5.1. Hospital Pharmacies
- 13.5.2. Retail Pharmacies
- 13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.6.1. China
- 13.6.2. Japan
- 13.6.3. India
- 13.6.4. Australia & New Zealand
- 13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
- 13.7.1. By Drug Class
- 13.7.2. By Route of Administration
- 13.7.3. By Indication
- 13.7.4. By Distribution Channel
- 13.7.5. By Country/Sub-region

14. Latin America Anticoagulants Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017-2031
- 14.2.1. Factor XA Inhibitors (NOAC/DOAC)
- 14.2.2. Heparins
- 14.2.3. Direct Thrombin Inhibitors
- 14.2.4. Vitamin K Antagonists
14.3. Market Value Forecast, by Route of Administration, 2017-2031
- 14.3.1. Oral
- 14.3.2. Injectable
14.4. Market Value Forecast, by Indication, 2017-2031
- 14.4.1. Deep Vein Thrombosis
- 14.4.2. Pulmonary Embolism
- 14.4.3. Atrial Fibrillation & Heart Attack
- 14.4.4. Ischemic Stroke
- 14.4.5. Others
14.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 14.5.1. Hospital Pharmacies
- 14.5.2. Retail Pharmacies
- 14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.6.1. Brazil
- 14.6.2. Mexico
- 14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
- 14.7.1. By Drug Class
- 14.7.2. By Route of Administration
- 14.7.3. By Indication
- 14.7.4. By Distribution Channel
- 14.7.5. By Country/Sub-region

15. Middle East & Africa Anticoagulants Market Analysis and Forecast

15.1. Introduction
- 15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2017-2031
- 15.2.1. Factor XA Inhibitors (NOAC/DOAC)
- 15.2.2. Heparins
- 15.2.3. Direct Thrombin Inhibitors
- 15.2.4. Vitamin K Antagonists
15.3. Market Value Forecast, by Route of Administration, 2017-2031
- 15.3.1. Oral
- 15.3.2. Injectable
15.4. Market Value Forecast, by Indication, 2017-2031
- 15.4.1. Deep Vein Thrombosis
- 15.4.2. Pulmonary Embolism
- 15.4.3. Atrial Fibrillation & Heart Attack
- 15.4.4. Ischemic Stroke
- 15.4.5. Others
15.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 15.5.1. Hospital Pharmacies
- 15.5.2. Retail Pharmacies
- 15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 15.6.1. GCC Countries
- 15.6.2. South Africa
- 15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
- 15.7.1. By Drug Class
- 15.7.2. By Route of Administration
- 15.7.3. By Indication
- 15.7.4. By Distribution Channel
- 15.7.5. By Country/Sub-region

16. Competition Landscape

16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Market Share/Ranking Analysis, by Company, 2021
16.3. Company Profiles
- 16.3.1. Bayer AG
  - 16.3.1.1. Company Overview
  - 16.3.1.2. Product Portfolio
  - 16.3.1.3. SWOT Analysis
  - 16.3.1.4. Strategic Overview
- 16.3.2. Boehringer Ingelheim International GmbH
  - 16.3.2.1. Company Overview
  - 16.3.2.2. Product Portfolio
  - 16.3.2.3. SWOT Analysis
  - 16.3.2.4. Strategic Overview
- 16.3.3. Bristol Myers Squibb
  - 16.3.3.1. Company Overview
  - 16.3.3.2. Product Portfolio
  - 16.3.3.3. SWOT Analysis
  - 16.3.3.4. Strategic Overview
- 16.3.4. Daiichi Sankyo Company
  - 16.3.4.1. Company Overview
  - 16.3.4.2. Product Portfolio
  - 16.3.4.3. SWOT Analysis
  - 16.3.4.4. Strategic Overview
- 16.3.5. Sanofi
  - 16.3.5.1. Company Overview
  - 16.3.5.2. Product Portfolio
  - 16.3.5.3. SWOT Analysis
  - 16.3.5.4. Strategic Overview
- 16.3.6. Johnson & Johnson
  - 16.3.6.1. Company Overview
  - 16.3.6.2. Product Portfolio
  - 16.3.6.3. SWOT Analysis
  - 16.3.6.4. Strategic Overview
- 16.3.7. Pfizer, Inc.
  - 16.3.7.1. Company Overview
  - 16.3.7.2. Product Portfolio
  - 16.3.7.3. SWOT Analysis
  - 16.3.7.4. Strategic Overview

抗凝固剤の世界市場：薬剤クラス（第XA因子阻害剤（NOAC/DOAC）、ヘパリン、直接トロンビン阻害剤、ビタミンK拮抗剤）－業界分析、市場規模、シェア、成長、動向、予測（2022年～2031年）

Anticoagulants Market (Drug Class: Factor XA Inhibitors [NOAC/DOAC], Heparins, and Direct Thrombin inhibitors, and Vitamin K Antagonists) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

目次

第1章序文

第2章前提と調査手法

第3章エグゼクティブサマリー：世界の抗凝固薬市場

第4章市場概要

第5章主な洞察

第6章世界の抗凝固薬市場の分析と予測：薬剤クラス別

第7章世界の抗凝固薬市場の分析と予測：投与経路別

第8章世界の抗凝固薬市場の分析と予測：適応症別

第9章世界の抗凝固薬市場の分析と予測：流通チャネル別

第10章世界の抗凝固薬市場の分析と予測：地域別

第11章北米の抗凝固薬市場の分析と予測

第12章欧州の抗凝固薬市場の分析と予測

第13章アジア太平洋の抗凝固薬市場の分析と予測

第14章ラテンアメリカの抗凝固薬市場の分析と予測

第15章中東およびアフリカの抗凝固薬市場の分析と予測

第16章競合情勢

List of Tables

List of Figures

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global Anticoagulants Market

4. Market Overview

5. Key Insights

6. Global Anticoagulants Market Analysis and Forecast, by Drug Class

7. Global Anticoagulants Market Analysis and Forecast, by Route of Administration

8. Global Anticoagulants Market Analysis and Forecast, by Indication

9. Global Anticoagulants Market Analysis and Forecast, by Distribution Channel

10. Global Anticoagulants Market Analysis and Forecast, by Region

11. North America Anticoagulants Market Analysis and Forecast

12. Europe Anticoagulants Market Analysis and Forecast

13. Asia Pacific Anticoagulants Market Analysis and Forecast

14. Latin America Anticoagulants Market Analysis and Forecast

15. Middle East & Africa Anticoagulants Market Analysis and Forecast

16. Competition Landscape

抗凝固剤の世界市場：薬剤クラス（第XA因子阻害剤（NOAC/DOAC）、ヘパリン、直接トロンビン阻害剤、ビタミンK拮抗剤）－業界分析、市場規模、シェア、成長、動向、予測（2022年～2031年）

Anticoagulants Market (Drug Class: Factor XA Inhibitors [NOAC/DOAC], Heparins, and Direct Thrombin inhibitors, and Vitamin K Antagonists) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

目次

第1章 序文

第2章 前提と調査手法

第3章 エグゼクティブサマリー：世界の抗凝固薬市場

第4章 市場概要

第5章 主な洞察

第6章 世界の抗凝固薬市場の分析と予測：薬剤クラス別

第7章 世界の抗凝固薬市場の分析と予測：投与経路別

第8章 世界の抗凝固薬市場の分析と予測：適応症別

第9章 世界の抗凝固薬市場の分析と予測：流通チャネル別

第10章 世界の抗凝固薬市場の分析と予測：地域別

第11章 北米の抗凝固薬市場の分析と予測

第12章 欧州の抗凝固薬市場の分析と予測

第13章 アジア太平洋の抗凝固薬市場の分析と予測

第14章 ラテンアメリカの抗凝固薬市場の分析と予測

第15章 中東およびアフリカの抗凝固薬市場の分析と予測

第16章 競合情勢

List of Tables

List of Figures

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global Anticoagulants Market

4. Market Overview

5. Key Insights

6. Global Anticoagulants Market Analysis and Forecast, by Drug Class

7. Global Anticoagulants Market Analysis and Forecast, by Route of Administration

8. Global Anticoagulants Market Analysis and Forecast, by Indication

9. Global Anticoagulants Market Analysis and Forecast, by Distribution Channel

10. Global Anticoagulants Market Analysis and Forecast, by Region

11. North America Anticoagulants Market Analysis and Forecast

12. Europe Anticoagulants Market Analysis and Forecast

13. Asia Pacific Anticoagulants Market Analysis and Forecast

14. Latin America Anticoagulants Market Analysis and Forecast

15. Middle East & Africa Anticoagulants Market Analysis and Forecast

16. Competition Landscape

第1章序文

第2章前提と調査手法

第3章エグゼクティブサマリー：世界の抗凝固薬市場

第4章市場概要

第5章主な洞察

第6章世界の抗凝固薬市場の分析と予測：薬剤クラス別

第7章世界の抗凝固薬市場の分析と予測：投与経路別

第8章世界の抗凝固薬市場の分析と予測：適応症別

第9章世界の抗凝固薬市場の分析と予測：流通チャネル別

第10章世界の抗凝固薬市場の分析と予測：地域別

第11章北米の抗凝固薬市場の分析と予測

第12章欧州の抗凝固薬市場の分析と予測

第13章アジア太平洋の抗凝固薬市場の分析と予測

第14章ラテンアメリカの抗凝固薬市場の分析と予測

第15章中東およびアフリカの抗凝固薬市場の分析と予測

第16章競合情勢